BMS delays Alzheimer’s readout for Cobenfy over “site irregularities”
Cobenfy received approval from the FDA in schizophrenia in September 2024.
Therapy Area
Belite eyes tinlarebant approval after late-stage Stargardt success
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs
Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes
Innovent boasts another pivotal trial success for obesity drug
Coya Therapeutics hopes for ALS Treg approval on Phase II trial
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
